Close Menu

KRAS Biomarkers

News and reporting on KRAS biomarkers.

Trovagene said today that it has entered into a collaboration with the University of Texas MD Anderson Cancer Center to detect transrenal BRAF mutations in the urine of patients with advanced or metastatic cancers.

Momentum from the 2011 launch of two highly anticipated personalized medicine cancer treatments — Pfizer's Xalkori and Roche's Zelboraf — continued to spur pharmaceutical companies and test makers to engage in drug and diagnostic codevelopment collaborations throughout 2012.

Amgen said this week that its $415 million proposed acquisition of Icelandic genetics research firm Decode will bolster its ability to evaluate which molecules to advance through its pipeline.

Trovagene this week said that it has completed development of its first molecular diagnostic, a transrenal assay for detecting KRAS mutations, and expects to transfer the assay to its CLIA lab next month and offer the test commercially in January.

Testing for gene mutations that hinder the ability of colorectal cancer patients to respond to anti-EGFR drugs is a cost-effective way of administering such pricey treatments, according to

Transgenomic has been awarded a Phase I Small Business Technology Transfer grant from the National Institutes of Health to conduct initial studies on the feasibility of using Ice-Cold-PCR for the early detection of pancreatic cancer.

Trovagene, MD Anderson Collaborate to ID KRAS Mutations in Pancreatic Cancer Patients' Urine

Pages

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.